Executive Summary
Transfemoral TMVR has arrived as a real option for high-risk mitral regurgitation patients, with the CHOICE-MI registry in JACC: Cardiovascular Interventions reporting 91.1% technical success and residual MR ≤1+ in 94.9% at discharge across 124 patients treated with nine different devices — but at a steep price: 44.1% mortality or heart failure hospitalization at one year, rising to 52.4% at two. The same JACC:CI issue delivers the tricuspid field a crisp new prognostic tool: post-procedure VExUS grade 3 predicts mortality after TTVI (HR 5.55, 95% CI 1.60-19.21). And 11.0% of TAVR patients without baseline AV valve disease developed new MR or TR within three years, with significantly higher all-cause and CV mortality — complicating the assumption that relieving outflow obstruction reliably reverses downstream valve disease.
- CHOICE-MI TF-TMVR: technical success 91.1%, 30-day mortality 0.8%, but 2-year composite mortality/HF hospitalization 52.4% — high-risk cohort, non-randomized, N=124 (JACC:CI).
- VExUS grade 3 at 24 hours post-TTVI is a strong independent mortality predictor; 66% of patients reclassified to grade ≤1 within a day of intervention (JACC:CI).
- New MR/TR after TAVR occurred in 11% of 1,034 patients with no baseline AV valve disease and drove significantly higher 3-year mortality (Clin Res Cardiol).
- Low-flow AS phenotype shapes MR trajectory after TAVR: classical LFLG had the highest MR worsening and worst event-free survival across 614 patients (medRxiv preprint).
- Edwards Lifesciences (EW) closed +2.57% to $92.03, up 16% over six months and now trading within 4% of its 52-week high on renewed TAVR growth optimism (MarketWatch).
What to watch: Medtronic's fiscal Q1 earnings on September 1 will offer the next read on Evolut share against Edwards' PARTNER-3 tailwind and the widening SAPIEN/Evolut market split.
Aortic Valve (TAVR/TAVI)
Two findings undercut the tidy narrative that TAVR fixes downstream valves along with the aortic outflow. The Munich group reported in Clinical Research in Cardiology that 11.0% of 1,034 patients with severe AS but no baseline MR or TR developed new-onset moderate-or-greater atrioventricular valve regurgitation after TAVR — 75 isolated MR, 22 isolated TR, 17 combined — and those patients had significantly higher 3-year all-cause (p<0.01) and cardiovascular (p<0.001) mortality. The authors frame this as an independent entity, not a late-stage bystander, which if confirmed reframes pre-TAVR risk stratification. Retrospective and single-center, but the signal is clean. Neither ACC/AHA 2020 nor ESC 2025 address post-TAVR de novo AV valve disease as a discrete risk category; this data argues that pre-procedural phenotyping for downstream valve susceptibility belongs in the workup.
[NOTABLE] A medRxiv preprint from Mount Sinai (N=614 low-flow AS patients, non-peer-reviewed) shows MR trajectory after TAVR is phenotype-specific: classical LFLG carries the highest rate of MR worsening at 30 days and the lowest event-free survival, while low-flow high-gradient patients fare best. ACC/AHA 2020 and ESC 2025 both default to Class I intervention across the low-flow AS group without phenotype-specific decision pathways. The Mount Sinai data argues for pre-procedural phenotyping and, in cLFLG patients with borderline MR, considering concomitant surgical mitral repair rather than TAVR-first optimism — though that hypothesis requires prospective validation before it alters practice.
An engineering paper in Cardiovasc Eng Technol extends the Reverse Calcification Technique into a time-parametric model of AS progression, with 7-8% relative error for scan intervals under three years across 17 patients. Interesting for research; not yet clinical.
Mitral Valve (MitraClip, PASCAL, TMVR)
[NOTABLE] The CHOICE-MI registry in JACC:CI pooled 124 TF-TMVR patients across 41 international centers using 9 different devices, median age 79, EuroSCORE II 5.0%. Technical success 91.1%, procedural mortality 0.8%, residual MR ≤1+ in 94.9% at discharge and durable at follow-up. The catch: 1-year mortality/HF hospitalization 44.1%, 2-year 52.4%, with atrial fibrillation as an independent predictor of the composite. The accompanying editorial "The Coming of Age of Transfemoral TMVR" reads more triumphally than the numbers support — this is a high-risk, non-randomized registry across heterogeneous devices, and half the cohort is dead or rehospitalized within two years.
The surgical counterpoint is unavoidable. ESC 2025 upgraded MV repair for asymptomatic primary MR with preserved LV to Class I when 3+ risk factors are present; TEER remains Class IIa for high-risk symptomatic primary MR. TF-TMVR sits nowhere in current guideline recommendations. The 39.5% primary MR fraction in CHOICE-MI is the population where durable surgical repair — carrying 1-2% mortality at experienced centers — remains the benchmark. Contemporary MV repair mortality at high-volume centers is an order of magnitude below CHOICE-MI's 2-year composite. TF-TMVR is a legitimate late-line option for patients rejected for surgery; it is not a repair alternative.
A separate JACC:CI report describes acute intraprocedural mitral annuloplasty during TMVR with a valve-in-ring system, and Cologne investigators describe M-TEER for progressive MR after TTVR in biatrial dilation — pointing to the emerging problem of sequential AV valve intervention in atrial-driven disease, a phenotype the ESC 2025 formally recognizes as atrial secondary MR but for which no transcatheter pathway has yet reached Class I evidence.
Tricuspid Valve (TriClip, TTVR)
The headline finding from JACC:CI: VExUS score improves within 24 hours of TTVI, with 66% of patients moving from grade 3 to ≤1 despite no change in diuretic dose or weight, and post-procedure VExUS grade 3 independently predicts mortality (HR 5.55, 95% CI 1.60-19.21, p=0.007). N=64, prospective multicenter, 76.7% women, mixed device types (60.9% edge-to-edge, 18.7% annuloplasty, 14.1% orthotopic replacement). Small, but the signal is coherent and hemodynamically plausible. ESC 2025 rates transcatheter TV treatment Class IIa (LOE A) for high-risk symptomatic severe TR; ACC/AHA 2020 offers no recommendation. VExUS as a post-procedural risk stratifier fills a gap neither guideline addresses.
A companion 3D-echo study validates volumetric RV-PA coupling as a prognostic marker for T-TEER, and pulmonary artery pulsatility index emerged as a hemodynamic predictor for TTVR — the field is finally getting the risk-stratification tools it needed to operationalize the ESC IIa recommendation responsibly. A separate report on recurrent TR after TTVR and redo T-TEER after prior surgical or transcatheter repair establishes that reintervention is now a real clinical entity requiring formal management pathways. The JoVE technical paper on structured EVOQUE implantation reflects the same trend: procedural standardization is catching up to enthusiasm, which is necessary before volumes can scale.
Surgical vs. Transcatheter Comparisons
No head-to-head trials today. The CHOICE-MI TF-TMVR 2-year composite of 52.4% mortality/HF hospitalization needs to be read against contemporary MV repair mortality of 1-2% in experienced centers for primary MR. Even accounting for the CHOICE-MI cohort being older, higher-risk, and often turned down for surgery, the durability gap between surgical repair and any transcatheter mitral replacement remains vast. The ESC 2025 upgrade of primary MR repair to Class I in preserved-LV asymptomatic patients with 3+ risk factors reflects that reality, and today's transcatheter data do not move that needle.
Preprint Highlights
The Mount Sinai LFAS-MR trajectory preprint is the substantive one — phenotype-informed post-TAVR surveillance is a testable, actionable hypothesis, pending peer review. The PEG hydrogel formulation study on bioRxiv is bench-side polymer chemistry with downstream relevance to assay design; not directly applicable to valve practice today.
Device & Technology
A JACC:CI case report describes aortic valve leaflet liberation under intravalvular ICE guidance — reflecting the growing use of ICE for TAVR planning and BASILICA-type procedures. Editorial commentary in the same issue on implantation depth in self-expanding TAVR reinforces that CoreValve/Evolut outcomes remain highly technique-sensitive, a durability concern that sharpens as lifetime management planning becomes central to patients under 70 per ESC 2025 guidance. Getting implantation depth right at the index procedure is not a technical footnote — it determines valve-in-valve feasibility, coronary access, and conduction outcomes across a patient's remaining decades.
Regulatory & Policy
No FDA, CMS, or EMA actions reported today.
Industry & Market
Edwards attracted analyst and institutional attention: DirectorsTalk highlighted a $100.96 consensus target with 12.5% upside, and Renaissance Technologies added 29,000 shares. The setup: EARLY TAVR asymptomatic AS data and ESC 2025's TAVI-at-70 expansion feed a bull thesis on TAVR volume growth that Edwards is best positioned to capture with SAPIEN.
Financial Analysis
The Edwards-Boston Scientific divergence is the story. EW is up 16% over six months, sitting near its 52-week high on TAVR growth and asymptomatic-AS expansion optimism. BSX is down 31% over six months — the TriClip franchise has not delivered the growth trajectory the market had priced, and TRISCEND II's read-out on TTVR raised competitive threats. Today's JACC:CI evidence that transcatheter tricuspid outcomes depend heavily on venous congestion status and RV-PA coupling — variables that select against many real-world referrals — means TR volumes will grow more slowly than the aortic curve. Abbott and Medtronic sit in the middle, with MDT's Evolut franchise facing durability and PPM headwinds against SAPIEN in the low-risk expansion zone.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $92.03, +2.57% today, +16.01% over 6 months, near 52-week high of $96.29
- Market cap $53.0B | Trailing P/E 53.5 | Forward P/E 27.3 | Beta 0.85
- Analyst consensus target $100.96 (range $84-$110, 26 analysts), Buy
- Next earnings 2026-10-29, EPS est $0.74, revenue est $1.68B
- The pure-play TAVR name benefits most from EARLY TAVR asymptomatic-AS uptake and ESC 2025's expanded TAVI-preferred zone; today's Munich data on new AV valve regurgitation post-TAVR is a mild counter-current but unlikely to slow volume growth.
Medtronic (MDT)
- Close $89.41, +2.58% today, -10.02% over 6 months
- Market cap $114.4B | Trailing P/E 23.3 | Forward P/E 13.9 | Beta 0.57
- Analyst consensus target $98.44 (range $78-$121, 25 analysts), Buy
- Next earnings 2026-09-01, EPS est $1.39, revenue est $9.55B
- Evolut faces continued PPM and depth-of-implantation scrutiny per today's JACC:CI editorial; the September earnings will test whether Evolut FX Plus adoption offsets share pressure from SAPIEN in low-risk younger patients.
Abbott (ABT)
- Close $108.62, +0.75% today, -3.09% over 6 months
- Market cap $188.0B | Trailing P/E 34.8 | Forward P/E 17.9 | Beta 0.58
- Analyst consensus target $118.42 (range $103-$135, 24 analysts), Buy
- Next earnings 2026-10-14, EPS est $1.42, revenue est $12.99B
- MitraClip and TriClip franchises face a maturing SMR TEER market (ESC 2025 Class I helps in Europe) and rising competition from PASCAL and emerging TMVR devices like those in CHOICE-MI.
Boston Scientific (BSX)
- Close $50.46, +2.33% today, -31.32% over 6 months
- Market cap $73.1B | Trailing P/E 19.9 | Forward P/E 14.7 | Beta 0.57
- Analyst consensus target $62.69 (range $44-$94, 29 analysts), Buy
- Next earnings 2026-10-28, EPS est $0.81, revenue est $5.26B
- The steep 6-month drawdown reflects TAVR-adjacent portfolio pressure and slower-than-modeled structural heart growth; today's tricuspid evidence base tightens patient selection, which cuts both ways for near-term volume.
Anteris Technologies (AVR.AX)
- Close A$12.55, +4.50% today, +55.51% over 6 months
- Market cap A$1.2B | Forward P/E -5.76 | Beta 0.73
- Single analyst target A$13.00
- The DurAVR balloon-expandable single-piece bovine pericardium valve continues to draw speculative interest on differentiated hemodynamics; commercial and regulatory pathways remain the binding constraints.
Market outlook: The valve group split — EW up 16%, BSX down 31% over six months — reflects a market separating pure TAVR beneficiaries from diversified structural heart franchises facing slower-than-hoped tricuspid and mitral adoption curves. Today's JACC:CI evidence supports better tricuspid patient selection but does not accelerate procedural volumes.
Clinical Trial Updates
Aortic:
- NCT07677410 — Aspirin Monotherapy Versus Sequential Warfarin-Aspirin Therapy After TAVR in Patients With Pure Aortic Regurgitation. Status: Recruiting. Enrollment: 1,172. Sponsor: Shanghai Zhongshan Hospital. A pragmatic anticoagulation strategy trial in a growing off-label TAVR-for-AR population; ESC 2025 introduced TAVI for AR at Class IIb for inoperable patients, so post-procedure antithrombotic strategy is an open question this trial can meaningfully answer.
Mitral Replacement:
- NCT07130994 — CASSINI-US. Reduction or Elimination of Mitral Regurgitation With the SATURN TMVR System. Status: Recruiting. Enrollment: 15. Sponsor: InnovHeart. Early feasibility for another entry into the crowded TMVR device space CHOICE-MI just characterized — nine devices, no dominant platform.
Social & Conference Highlights
No conference activity today; TCT 2026 remains the next major structural heart data drop on the calendar, with expected updates on EARLY TAVR extended follow-up, TRISCEND II mid-term outcomes, and additional TMVR device cohorts.
The evidence base for transcatheter mitral and tricuspid intervention is thickening on registries and mechanistic surrogates. The durability, patient-selection, and comparative-effectiveness questions that separate today's practice from settled guideline positions remain wide open — a gap Medtronic's September earnings and TCT 2026 will begin to close.